Neuren Pharmaceuticals (ASX:NEU) reported that primary endpoints for its planned single phase-three clinical trial of its drug candidate NNZ-2591 as a treatment for Phelan-McDermid syndrome were confirmed at a meeting with the US Food and Drug Administration, according to a Monday Australian bourse filing.
The co-primary endpoints in the double-blind placebo-controlled study of treatment for 13 weeks will be the change from baseline in the receptive communication sub-domain of the Vineland adaptive
behavior scales, third edition, and the overall score in the Phelan-McDermid syndrome assessment of change.
The firm said it remains on track to commence the phase three trial by the middle of the year, subject to regulatory review of the final version of the trial protocol.
Both measures included in the primary endpoints showed clinically meaningful improvement in the firm's phase two open-label clinical trial, the filing noted.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。